NCT03774875: A reported trial by Amgen
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03774875 |
|---|---|
| Title | A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2019 |
| Completion date | Feb. 1, 2021 |
| Required reporting date | Feb. 1, 2022, midnight |
| Actual reporting date | Dec. 14, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |